Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized transplant intervention trial in adults with AML or high-risk MDS
ISRCTN12434060Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Jan 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cytarabine, thiotepa, busulfan, fludarabine and amsacrine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (7 arms), sponsored by University of Birmingham. Primary endpoint: Overall survival. Started Jan 2020; status: completed.
02
Drugs
cytarabinethiotepabusulfanfludarabineamsacrine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN12434060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12434060.